Dentsply (XRAY) - Forward Price-to-Revenue Multiple

dentsplysirona.com (XRAY) - corporate logo

DENTSPLY SIRONA Inc. (XRAY) controls a comprehensive dental environment by integrating equipment and consumables. The company's forward P/S reflects market expectations, where 0.50 is established as the baseline value. Stable cash flow is driven by the inertia of regular clinic procurement. Meanwhile, management is successfully restoring confidence through strict compliance and the optimization of asset portfolio margins.

XRAY dentsplysirona.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/17/2026

Dentsply Sirona - analytical breakdowns and key metrics (XRAY)

- market price and analyst price targets:
General company analysis:XRAY (Sirona Dental Systems)
Original product of dentsplysirona.com

The digitalization of dental equipment and the implementation of 3D solutions by DENTSPLY SIRONA Inc. (XRAY) create a foundation for revenue scaling. By analyzing the forward P/S ratio, an investor assesses capitalization dynamics relative to expected sales, which determines whether the current market multiple is justified by the pace of business expansion or if the asset faces a correction should operational growth slow.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Danaher Corporation Inc. DHR|BDX - Price-to-Projected Revenue Ratio|STERIS plc (STE) - Forward Price-to-Revenue Multiple|WST: Forward P/S Multiple|Market Cap to Future Revenue Ratio Baxter International Inc. (BAX)|MASI (masimo.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group Corp STVN|Forward Price-to-Revenue Multiple TFX (Teleflex Inc)|Merit Medical - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (ICU Medical Inc)|LMAT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio AtriCure Corp ATRC|staar.com (STAA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ChromaDex Corporation|ZIMV (ZimVie Inc) - Forward P/S Multiple|Market Cap to Projected Revenue ANGO (AngioDynamics)|Price-to-Projected Revenue Ratio Cerus Corp (CERS)|TKNO: Future Price to Revenue|Price-to-Projected Revenue Ratio Monogram Technologies Inc. MGRM|Forward Price to Sales STSS|INFU - Price-to-Projected Revenue Ratio|Forward Price to Sales UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Projected Revenue Ratio|Nyxoah S.A. - Forward Price to Sales|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com